TP53 mutation and survival in aggressive B cell lymphoma

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• TP53 mutations occur in 20-25% of aggressive B-cell lymphoma (B-NHL).
• Previous studies have not assessed TP53 mutation impact in prospective clinical trials.
• The RICOVER-60 trial provides a prospective cohort to evaluate TP53's role.

Purpose of the Study:

• To evaluate the impact of TP53 mutations on current risk models in aggressive B-NHL.
• To assess TP53 mutation as an independent prognostic factor for survival outcomes.
• To determine the clinical significance of TP53 mutations in elderly B-NHL patients.

Main Methods:

• Analysis of TP53 gene mutations in 265 elderly patients (61-80 years) from the RICOVER-60 trial.
• Patients were randomized to CHOP-14 with or without Rituximab.
• Cox proportional hazard analysis was used to assess independent predictors of survival.

Main Results:

• TP53 mutations were found in 23.8% of analyzed patients and associated with higher LDH, IPI scores, and B-symptoms.
• Patients with TP53 mutations had lower complete remission rates (61.9% vs. 79.7%).
• TP53 mutations significantly decreased event-free survival (EFS), progression-free survival (PFS), and overall survival (OS).

Conclusions:

• TP53 mutations are independent predictors of EFS, PFS, and OS in aggressive CD20+ lymphoma.
• TP53 mutation status should be incorporated into risk models for diffuse large B-cell lymphoma (DLBCL).
• Novel therapeutic strategies are needed to improve outcomes for patients with TP53-mutated aggressive B-NHL.